Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
AVAILABLE
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302
Sponsor: Idorsia Pharmaceuticals Ltd.
View on ClinicalTrials.gov
Summary
This is a Post Trial Access program for patients with Fabry Disease who previously participated in the ID-069A302 (MODIFY OLE) trial and who were still enrolled in the study at the time the Sponsor decided to discontinue ID-069A302. The program is designed to provide continued access to lucerastat.
Key Details
Gender
Not specified
Age Range
Any - Any
Study Type
EXPANDED_ACCESS
Enrollment
Not specified
Start Date
Not specified
Completion Date
Not specified
Last Updated
2026-08-13
Healthy Volunteers
Not specified
Conditions
Interventions
DRUG
Lucerastat